Achillion (ACHN) investors got a huge piece of bad news on Monday evening, when this biotech virology specialist announced that its lead protease inhibitor for hepatitis C (HCV), sovaprevir, has been placed on clinical hold by the FDA after troubling safety data. With the stock down sharply in after-hours trading, this is clearly a major near-term problem for the company and the stock, and it definitely raises troubling questions about the safety profile of this drug.
While I do not believe this development devastates the long-term potential of the drug in HCV treatment, it most likely freezes any possibility of an acquisition and it is almost certainly going to appear as an issue if/when the company files...
Only subscribers can access this article, which is part of the PRO research library covering 3,588 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: